(a) Subsidy restrictions: trastuzumab for HER2+ metastatic breast cancer | ||
---|---|---|
2001–2005 | 2006–2015 | 2015—present* |
Treatment qualification: patients must have HER2 overexpression by | ||
▸ IHC 3+ or ISH | ISH | No change |
Trastuzumab treatment | ||
| As per 2001–2005 plus
| As per 2001–2015 plus
|
Cardiac monitoring | ||
▸ None required | None required |
|
(b) Subsidy restrictions: trastuzumab for HER2+ early breast cancer | ||
2006–2015 | 2015—present | |
Treatment qualification: patients must have… | ||
| No change | |
Trastuzumab treatment | ||
| No change | |
Cardiac monitoring | ||
| No change | |
(c) Subsidy restrictions: lapatinib for HER2+ metastatic breast cancer | ||
2008–2010 | 2010–2015 | 2015—present |
Treatment qualification: patients must have… | ||
| No change | No change |
Lapatinib treatment | ||
|
| No change |
Cardiac monitoring | ||
▸ ECHO or MUGA at baseline then at discretion of clinician | No change |
|
(d) Subsidy restrictions: trastuzumab for HER2+ neoadjuvant therapy | ||
2012—present | ||
Treatment qualification: patients must have… | ||
| ||
Trastuzumab treatment | ||
| ||
| ||
(e) Subsidy restrictions: pertuzumab for HER2+ metastatic breast cancer | ||
2015—present | ||
Treatment qualification: patients must have… | ||
| ||
Pertuzumab treatment | ||
| ||
Cardiac monitoring | ||
| ||
(f) Subsidy restrictions: Trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer | ||
2015–2016 | 2016—present | |
Treatment qualification: patients must have | ||
| As per 2015–2016 but
| |
T-DM1 treatment | ||
| No change | |
Cardiac monitoring | ||
| No change |
*Herceptin Programme ceased and trastuzumab for MBC was listed on the PBS.
ECHO, echocardiography; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridisation; MBC, metastatic breast cancer; MUGA, multiple gated acquisition scan; PBS, Pharmaceutical Benefits Scheme.